Image_1_Interleukin 33 Selectively Augments Rhinovirus-Induced Type 2 Immune Responses in Asthmatic but not Healthy People.tif
Interleukin- 33 (IL-33) is an epithelial-derived cytokine that initiates type 2 immune responses to allergens, though whether IL-33 has the ability to modify responses to respiratory viral infections remains unclear. This study aimed to investigate the effects of IL-33 on rhinovirus (RV)-induced immune responses by circulating leukocytes from people with allergic asthma, and how this response may differ from non-allergic controls. Our experimental approach involved co-exposing peripheral blood mononuclear cells to IL-33 and RV in order to model how the functions of virus-responsive lymphocytes could be modified after recruitment to an airway environment enriched in IL-33. In the current study, IL-33 enhanced RV-induced IL-5 and IL-13 release by cells from people with allergic asthma, but had no effect on IL-5 and IL-13 production by cells from healthy donors. In asthmatic individuals, IL-33 also enhanced mRNA and surface protein expression of ST2 (the IL-33 receptor IL1RL1), while soluble ST2 concentrations were low. In contrast, IL-33 had no effect on mRNA and surface expression of ST2 in healthy individuals. In people with allergic asthma, RV-activated ST2+ innate lymphoid cells (ST2+ILC) were the predominant source of IL-33 augmented IL-13 release. In contrast, RV-activated natural killer cells (NK cells) were the predominant source of IL-33 augmented IFNγ release in healthy individuals. This suggests that the effects of IL-33 on the cellular immune response to RV differ between asthmatic and healthy individuals. These findings provide a mechanism by which RV infections and IL-33 might interact in asthmatic individuals to exacerbate type 2 immune responses and allergic airway inflammation.
History
References
- https://doi.org//10.1086/514634
- https://doi.org//10.1067/mai.2000.104785
- https://doi.org//10.1164/rccm.201708-1762OC
- https://doi.org//10.1073/pnas.0804181105
- https://doi.org//10.1136/thorax.57.4.328
- https://doi.org//10.1164/rccm.201406-1039OC
- https://doi.org//10.1111/cea.12683
- https://doi.org//10.1016/j.jaci.2013.12.1080
- https://doi.org//10.1073/pnas.1601914113
- https://doi.org//10.1038/nri.2016.95
- https://doi.org//10.1038/srep43426
- https://doi.org//10.1016/j.cyto.2008.03.008
- https://doi.org//10.1165/rcmb.2010-0516OC
- https://doi.org//10.1016/j.jaci.2017.07.051
- https://doi.org//10.1183/09031936.00172008
- https://doi.org//10.1016/j.jaci.2014.11.037
- https://doi.org//10.1016/j.jaci.2015.05.037
- https://doi.org//10.1016/j.imbio.2015.02.005
- https://doi.org//10.1038/ni.3370
- https://doi.org//10.1073/pnas.1418549112
- https://doi.org//10.1016/j.jaci.2014.06.023
- https://doi.org//10.1016/j.jaci.2012.11.028
- https://doi.org//10.1016/j.jaci.2016.07.017
- https://doi.org//10.1186/1465-9921-11-184
- https://doi.org//10.1016/j.jaci.2017.02.038
- https://doi.org//10.3389/fimmu.2017.01684
- https://doi.org//10.4049/jimmunol.1601984
- https://doi.org//10.1164/rccm.200306-737OC
- https://doi.org//10.1038/nature14115
- https://doi.org//10.1016/j.jaci.2015.12.1325
- https://doi.org//10.1183/13993003.00400-2015
- https://doi.org//10.4049/jimmunol.1601830
- https://doi.org//10.1016/j.jaci.2017.04.043
- https://doi.org//10.3109/02770903.2015.1026441
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity